Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 9/20 | 0.74 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421754 | 1.00 | NTSR1 (0.74) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL30880437 | 0.95 | NTSR1 (0.82) | NTSR1NTSR2SORT1 | |
| SCHEMBL1421938 | 0.94 | OPRD1 (0.69) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL1421888 | 0.94 | OPRD1 (0.69) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL1421931 | 0.94 | OPRD1 (0.69) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL1421906 | 0.94 | OPRD1 (0.69) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL31124658 | 0.93 | OPRD1 (0.67) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL12521276 | 0.93 | OPRD1 (0.68) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL29583282 | 0.92 | NTSR1 (0.73) | NTSR1NTSR2OPRD1SORT1 | |
| SCHEMBL29702258 | 0.92 | NTSR1 (0.73) | NTSR1NTSR2OPRD1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551939-B2 | Peptide analogues, particularly for the treatment of chronic pain | INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ (PL) | 2013-10-08 | — | — | US | claimed |
| EP-2297179-B1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | INST MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ IM MIROSLAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK (PL) | 2012-09-26 | — | — | EP | claimed |
| US-20110166083-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ (PL) | 2011-07-07 | — | — | US | claimed |
| EP-2297179-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | Instytut Medycyny Doswiadczalnej I Klinicznej Im. Miroslawa Mossakowskiego Polskiej Akademii Nauk (PL) | 2011-03-23 | — | — | EP | claimed |
| WO-2009148343-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | INSTYTUT MEDYCYNY DOŚWIADCZALNEJ I KLINICZNEJ IM. MIROSŁAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK (PL) | 2009-12-10 | — | — | WO | claimed |
| US-8551939-B2 | Peptide analogues, particularly for the treatment of chronic pain | INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ (PL) | 2013-10-08 | — | — | US | disclosed |
| EP-2297179-B1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | INST MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ IM MIROSLAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK (PL) | 2012-09-26 | — | — | EP | disclosed |
| US-20110166083-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ (PL) | 2011-07-07 | — | — | US | disclosed |
| EP-2297179-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | Instytut Medycyny Doswiadczalnej I Klinicznej Im. Miroslawa Mossakowskiego Polskiej Akademii Nauk (PL) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009148343-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | INSTYTUT MEDYCYNY DOŚWIADCZALNEJ I KLINICZNEJ IM. MIROSŁAWA MOSSAKOWSKIEGO POLSKIEJ AKADEMII NAUK (PL) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166083-A1 | PEPTIDE ANALOGUES, PARTICULARLY FOR THE TREATMENT OF CHRONIC PAIN | OPRL1, OPRK1, NTSR2 | NTSR1 4/4885NTSR2 3/4885OPRD1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.